Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • NovoCure receives consensus “Hold” rating from eight analysts, according to MarketBeat Ratings.
  • Average 12-month target price stands at USD 27.50 among recently rated brokerages.
  • Institutional investors hold around 84.6% of NovoCure’s outstanding shares.

NovoCure Limited (NASDAQ:NVCR) has received an average recommendation of “Hold” from eight analysts covering the company, as reported by MarketBeat Ratings. Of these analysts, one assigned a “Sell” rating, three rated it as “Hold,” and four gave a “Buy” rating. The collective 12-month price target across these brokerages averages USD 27.50.

Several firms have recently commented on NovoCure’s valuation outlook:

  • Ladenburg Thalmann/SH SH began coverage on July 8 with a “Buy” rating and a price objective of USD 30.00.
  • Wells Fargo & Company reaffirmed an “Equal Weight” rating, adjusting its target from USD 40.00 to USD 14.50 on July 25.
  • Wedbush maintained a “Neutral” stance with an USD 18.00 target price on September 30.
  • Weiss Ratings issued a “Sell (e+)” rating on September 27.
  • Piper Sandler reiterated an “Overweight” rating and set a USD 34.00 target on June 27.

These mixed ratings reflect a cautious sentiment toward NovoCure’s near-term performance outlook among major brokerages.

Financial Performance and Metrics

For the recent quarter, NovoCure reported revenue of USD 158.8 million, exceeding analyst expectations of USD 153.87 million. The company’s revenue rose 5.6% year over year, while earnings per share stood at a loss of USD 0.31 during the same quarter last year. NovoCure reported a negative return on equity of 47.74% and a negative net margin of 27.13%.
Analysts currently forecast an annual EPS of approximately -1.3 for the ongoing fiscal year.

Insider Share Purchases

Recent filings show insider buying activity within the company:

  • CEO Ashley Cordova purchased 81,550 shares on September 5 at an average price of USD 12.22 per share, increasing total holdings to 437,569 shares.
  • CFO Christoph Brackmann acquired 20,000 shares on July 29 at an average of USD 11.59 per share, bringing total ownership to 141,150 shares.

Overall, around 5.52% of NovoCure’s shares are held by corporate insiders, reflecting moderate internal ownership alignment.

Institutional Investor Activity

Institutional investors collectively own about 84.61% of NovoCure’s shares. Key movements in recent quarters include:

  • GAMMA Investing LLC increased its holdings by 1,675%, now holding 49,967 shares valued at roughly USD 890,000.
  • Rhumbline Advisers raised its stake by 3.8%, reaching 150,952 shares valued at USD 2.69 million.
  • SG Americas Securities LLC, Simon Quick Advisors LLC, and Exchange Traded Concepts LLC also expanded or initiated new positions during the period.

Company Overview

NovoCure Limited is an oncology-focused medical device firm involved in developing and commercializing tumor treating fields (TTFields) therapies for solid tumor cancers across the U.S., Europe, Asia, and other global markets. Its key devices include Optune Gio and Optune Lua, designed for the clinical management of glioblastoma and other tumor types.